诺泰生物(688076) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥420,754,037.95, representing a year-on-year increase of 36.31%[2] - Net profit attributable to shareholders for the same period was ¥123,085,535.01, a significant increase of 146.86% compared to the previous year[2] - The net profit after deducting non-recurring gains and losses was ¥125,293,859.06, reflecting a year-on-year growth of 176.27%[2] - Basic earnings per share for Q3 2024 were ¥0.58, up 152.17% year-on-year, while diluted earnings per share were ¥0.56, an increase of 143.48%[4] - Year-to-date operating revenue as of Q3 2024 rose by 76.51% compared to the same period last year, with substantial increases in both self-selected and customized product revenues[8] - Net profit attributable to shareholders for Q3 2024 surged by 146.86% year-on-year, reflecting the growth in operating revenue and an increase in gross margin[8] - Year-to-date net profit attributable to shareholders reached a growth of 281.90% as of Q3 2024, supported by the same factors as the quarterly performance[8] - The net profit excluding non-recurring gains and losses for Q3 2024 increased by 176.27% year-on-year, indicating strong operational performance[8] - Year-to-date net profit excluding non-recurring gains and losses grew by 301.43% as of Q3 2024, consistent with the overall revenue growth[8] - Basic earnings per share for Q3 2024 increased by 152.17% compared to the same period last year, reflecting the significant rise in net profit[8] - The net profit for Q3 2024 reached CNY 350,696,470.09, a significant increase from CNY 90,339,373.11 in Q3 2023, representing a growth of approximately 288%[18] - Operating profit for Q3 2024 was CNY 389,429,394.38, compared to CNY 121,070,282.04 in the same period last year, indicating an increase of about 222%[18] - The total profit for Q3 2024 was CNY 385,239,321.13, up from CNY 114,846,980.22 in Q3 2023, reflecting an increase of approximately 235%[18] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,442,609,524.32, marking a 25.24% increase from the end of the previous year[4] - The company's total assets as of the end of Q3 2024 amounted to CNY 4,442,609,524.32, up from CNY 3,547,245,952.44 at the end of Q3 2023, representing a growth of 25.2%[16] - Current assets totaled CNY 1,831,306,768.96 in Q3 2024, compared to CNY 1,494,767,183.42 in Q3 2023, indicating an increase of 22.5%[15] - The company's total liabilities increased to CNY 1,803,567,908.44 in Q3 2024 from CNY 1,357,942,277.69 in Q3 2023, reflecting a rise of 32.7%[15] - The total equity attributable to shareholders was ¥2,616,678,543.03, up 20.57% from the previous year[4] - The total equity attributable to shareholders increased to CNY 2,616,678,543.03 in Q3 2024 from CNY 2,170,268,338.07 in Q3 2023, a growth of 20.5%[16] Research and Development - The company's R&D investment totaled ¥64,227,484.08 for the quarter, accounting for 15.26% of operating revenue, a decrease of 1.37 percentage points year-on-year[4] - Research and development expenses for the year-to-date period reached 99.08 million RMB, indicating an increase due to the progress of ongoing projects[8] - Research and development expenses surged to CNY 172,750,863.81 in the first three quarters of 2024, compared to CNY 85,401,759.00 in 2023, marking an increase of 102.5%[17] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥267,304,297.88, reflecting a 13.67% increase[4] - Cash flow from operating activities for the first three quarters of 2024 was CNY 1,137,418,208.44, up from CNY 746,154,754.78 in the previous year, reflecting a growth of approximately 52%[21] - The company reported a net cash outflow from investing activities of CNY -840,263,367.82 for the first three quarters of 2024, compared to CNY -478,683,946.08 in the previous year[22] - The company received CNY 1,240,000,000.00 from investment recoveries in the first three quarters of 2024, compared to CNY 465,750,000.00 in the same period last year, indicating a substantial increase[21] Inventory and Borrowings - The company reported a significant increase in inventory, which reached CNY 521,105,440.80 in Q3 2024, compared to CNY 377,174,248.78 in Q3 2023, an increase of 38.0%[15] - The company’s short-term borrowings rose to CNY 987,828,099.87 in Q3 2024, compared to CNY 546,018,526.38 in Q3 2023, reflecting an increase of 80.7%[15] Other Income - The company reported a significant increase in other income, totaling CNY 981,200.39 in Q3 2024, compared to CNY 442,094.24 in Q3 2023[18]